- Launch of IUdo app helps patients on support programs by providing greater accessibility to Pfizer medications through a digitized patient journey
- Currently, the IUdo app is available to eligible patients who are part of Pfizer’s patient support programs in Qatar and will be rolling out to other emerging market countries over the coming months.
UAE — Pfizer remains true to its commitment to improving patient health and delivering breakthroughs that can change patients’ lives. As part of this commitment, the biopharmaceutical company continues to prioritize increasing affordability and overall access to medicines through its patient support programs.
As such, Pfizer launched an innovative digital platform, IUdo, for eligible patients in Qatar. The mobile app is designed to make it easier for patients in select patient support programs to access Pfizer medications. It improves both the patient and healthcare professional experience by speeding up program enrollment; provide seamless access to support treatment plans; increasing the scale and reach of programs for patients and allowing the support program journey to be managed directly from their phone.
The launch of the IUdo app also underscores Pfizer’s broader ambitions to leverage digital platforms and technologies that put effective and scalable solutions, including support programs, at the fingertips of patients. Such platforms can help better meet specific patient needs while improving the quality and convenience of care, and reducing the burden of ongoing and costly care.
“At Pfizer, our goal is to strengthen healthcare systems, improve access for patients who need it most, and support our communities. To be able to stay true to this, we are working to improve affordability and access to Pfizer medicines while improving the patient journey and experience through digital platforms. Thanks to the launch of this application in Qatar, Pfizer is at the forefront of digital innovation in the field of pharmaceutical health, particularly in the Gulf countries. Most importantly, we believe this tool will help bridge the gaps in the patient journey; allowing them to navigate, monitor and control the journey of their program, whenever they want, wherever they are,” said Parmjot Bains, Country Director, Pfizer Gulf Cluster.
Currently, the IUdo app is available to eligible patients who are part of Pfizer’s patient support programs in Qatar and will be rolling out to other emerging market countries over the coming months.
Currently, Pfizer supports 4,500 patients suffering from various oncological, inflammatory and rare diseases through 30 access programs in 11 countries in Africa and the Middle East (AfME). In 2022, Pfizer aspires to launch more than 5 new programs, in addition to expanding the scope of some current programs to include new treatments, with the goal of supporting the lives of more than 10,000 patients through AfME. Pfizer also operates several personalized support programs globally that provide patients with access to Pfizer medicines as well as financial assistance options.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring people therapies that dramatically extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we work with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For over 170 years, we’ve worked to make a difference for everyone who counts on us. We regularly post information that may be important to investors on our website at www.Pfizer.com.